SLRX
insider transactionsSalarius Pharmaceuticals, Inc. — buys & sells by directors, officers and 10% owners A shareholder owning more than 10% of the company. Must report trades, but usually a weaker signal than an officer or director. (SEC Form 4).
Net shares · 365d
-27
0 buy · 27 sell
Net value · 365d
-$17
$0 in · $17 out
Sentiment · 365d
Net selling
0% buying · 100% selling
Open-market trades · 365d
2
0 buy · 27 sell
Net buy / sell volume
Not enough data to chart yet.
Tap or hover the chart for daily net volume. Green = net buying, red = net selling.
All transactions
-
Sell·S
Director
$8
12 sh · $0.64
Own -100%
-
Sell·S
Director
$10
15 sh · $0.64
Own -0%
| Date▾ | Insider | Type | Shares | Value |
|---|---|---|---|---|
| Dec 30, 2025 | Arnold C Hanish | Sell S | 12 | $8 |
| Dec 30, 2025 | Arnold C Hanish | Sell S | 15 | $10 |
About SLRX insider trading
This page tracks insider transactions for Salarius Pharmaceuticals, Inc. (SLRX) reported to the U.S. Securities and Exchange Commission on Form 4. Corporate insiders — directors, executive officers and beneficial owners of more than 10% of the stock — must disclose their trades within two business days. Open-market purchases (code P) and sales (code S) made at the insider's discretion are the most-watched opportunistic signals, while awards (A), option exercises (M) and tax-withholding (F) reflect compensation rather than conviction. Trades marked 10b5-1 were made under a pre-arranged plan and are considered routine. A cluster buy — several insiders buying within a short window — is historically a stronger bullish indicator than any single trade.